BioVie Inc. Class A Common Stock (BIVI)
Stock · NASDAQ · Health Care
$1.2as of 10/16/2026
Price chart
Active signals
BIVI Signal Track Record
How signals performed across all stocks →What BIVI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | -4.7% | 40% | September 18, 2026 |
| Volume Spike | 23 | -15.5% | 39% | September 15, 2026 |
| Bollinger Band Breakout | 19 | -11.5% | 42% | June 22, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -19.0% | 25% | September 30, 2026 |
| Any 20-session window (baseline) | -6.9% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investig…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 13
- Website
- www.bioviepharma.com/
Fundamentals
- 1-day range
- $1.13$1.19
- Market cap
- $10.18M
- P/E (trailing)
- —
- P/E (forward)
- -1.98
- EPS (trailing)
- $-3.15
- Dividend yield
- —
- Beta
- 0.84
- Avg. volume
- 4.59M
- Dividend pay date
- November 22, 2019
Forecasts
2 analyst ratings
BioVie Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- BIVIBioVie Inc. Class A Common Stock$1.2▲ 6.19%Market cap $10.18MP/E —$0.82$3.79
- ADILAdial Pharmaceuticals Inc Common Stock$3.49▲ 11.15%Market cap $10.29MP/E —$1.31$232.5
- TOVXTheriva Biologics Inc. Common Stock$0.21▲ 0.00%Market cap $10.32MP/E —$0.1628$0.8632
- LSTALisata Therapeutics Inc. Common Stock$1.03▼ 3.74%Market cap $9.74MP/E —$0.98$5.07
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
- BFRGBullfrog AI Holdings Inc. Common Stock$0.513▼ 4.11%Market cap $10.96MP/E —$0.4251$1.96
- LNAILunai Bioworks Inc. Common Stock$0.68▼ 17.68%Market cap $10.97MP/E —$0.8757$13.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIVI BioVie Inc. Class A Common Stock | $10.18M | — | $1.2 | ▲ 6.19% | $0.82$3.79 |
| ADIL Adial Pharmaceuticals Inc Common Stock | $10.29M | — | $3.49 | ▲ 11.15% | $1.31$232.5 |
| TOVX Theriva Biologics Inc. Common Stock | $10.32M | — | $0.21 | ▲ 0.00% | $0.1628$0.8632 |
| LSTA Lisata Therapeutics Inc. Common Stock | $9.74M | — | $1.03 | ▼ 3.74% | $0.98$5.07 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
| BFRG Bullfrog AI Holdings Inc. Common Stock | $10.96M | — | $0.513 | ▼ 4.11% | $0.4251$1.96 |
| LNAI Lunai Bioworks Inc. Common Stock | $10.97M | — | $0.68 | ▼ 17.68% | $0.8757$13.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace GlobalYahoo · 9/26/2026
- BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets TranscriptSeekingAlpha · 9/23/2026
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace GlobalYahoo · 9/19/2026
- Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVYahoo · 9/18/2026
- BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid - SlideshowSeekingAlpha · 9/17/2026
- Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 ResultsYahoo · 9/16/2026
- BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full PopulationYahoo · 9/15/2026
- BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid TranscriptSeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Joseph M. Palumbo · August 28, 2026 · Buy4.8K @ $2.16
- Chappell Amy Suzon · August 28, 2026 · Buy727 @ $2.16
- Joanne Wendy Kim · August 28, 2026 · Buy2.5K @ $2.18
- Cuong Do V · August 27, 2026 · Buy15.2K @ $2.08
Institutional Ownership
March 31, 2026
- Total shares held
- 993.3K
- Total value held
- $1.25M
- Institutional holders
- 30
- Unknown370.0K
- Unknown92.1K
- Unknown84.2K
- Unknown84.1K
- Unknown75.2K
- Unknown75.0K
- Unknown67.9K
- Unknown45.3K
- Unknown23.5K
- Unknown22.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioVie Featured on Bloomberg Television Segment
BioVie was included in a new episode of The Street Show airing on Bloomberg Television. The segment also featured Glint, Sagtec Global, and SafeSpace Global. This media appearance provides additional visibility for the company to a financial audience.
BioVie Featured on Bloomberg Television Segment. BioVie was included in a new episode of The Street Show airing on Bloomberg Television. The segment also featured Glint, Sagtec Global, and SafeSpace Global. This media appearance provides additional visibility for the company to a financial audience.